OnabotulinumtoxinA (BOTOX®)A Review of its Use in the Prophylaxis of Headaches in Adults with Chronic Migraine

被引：0
作者：
James E. Frampton
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Migraine; Topiramate; Chronic Migraine; Medication Overuse; OnabotulinumtoxinA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This article reviews the pharmacology, therapeutic efficacy and tolerability profile of intramuscularly injected onabotulinumtoxinA (onaBoNTA; BOTOX®) for headache prophylaxis in adults with chronic migraine, with a focus on UK labelling for the drug. The pharmacological actions of onaBoNTA include a direct antinociceptive (analgesic) effect; while not fully understood, the mechanism of action underlying its headache prophylaxis effect in chronic migraine is presumed to involve inhibition of peripheral and central sensitization in trigemino-vascular neurones.
引用
收藏
页码：825 / 845
页数：20
相关论文
共 50 条
  • [31] Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union
    Matharu, M.
    Pascual, J.
    Remahl, I. Nilsson
    Odom, D.
    Gutierrez, L.
    Andrews, E.
    Largent, J.
    Johannes, C.
    JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [32] OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury
    Mark Sanford
    Drugs, 2014, 74 : 1659 - 1672
  • [33] Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
    Bendtsen, Lars
    Sacco, Simona
    Ashina, Messoud
    Mitsikostas, Dimos
    Ahmed, Fayyaz
    Pozo-Rosich, Patricia
    Martelletti, Paolo
    JOURNAL OF HEADACHE AND PAIN, 2018, 19 : 91
  • [34] Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
    Lars Bendtsen
    Simona Sacco
    Messoud Ashina
    Dimos Mitsikostas
    Fayyaz Ahmed
    Patricia Pozo-Rosich
    Paolo Martelletti
    The Journal of Headache and Pain, 2018, 19
  • [35] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Andrew M. Blumenfeld
    Sheena K. Aurora
    Karen Laranjo
    Spyros Papapetropoulos
    BMC Neurology, 15
  • [36] Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis
    Argyriou, Andreas A.
    Dermitzakis, Emmanouil, V
    Vlachos, George S.
    Vikelis, Michail
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 145 (06): : 676 - 683
  • [37] Use of botulinum toxin in chronic daily headaches associated with migraine
    Klapper, JA
    Klapper, A
    HEADACHE QUARTERLY-CURRENT TREATMENT AND RESEARCH, 1999, 10 (02): : 141 - 143
  • [38] OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
    Onan, Dilara
    Bentivegna, Enrico
    Martelletti, Paolo
    TOXINS, 2023, 15 (01)
  • [39] Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: A case report and literature review
    Gadient, Paul M.
    Smith, Jonathan H.
    Ryan, Stephen J.
    CEPHALALGIA, 2015, 35 (05) : 443 - 448
  • [40] Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis
    Zhao, Chengqi
    Li, Changxin
    Yu, Xueping
    Dai, Xiaohong
    Zou, Wei
    JOURNAL OF NEUROLOGY, 2024, 271 (09) : 5762 - 5777
12345